Cornea nerve fiber state determines analgesic response to tapentadol in fibromyalgia patients without effective endogenous pain modulation by Donk, T. van de et al.
Eur J Pain. 2019;00:1–10.    | 1wileyonlinelibrary.com/journal/ejp
1 |  INTRODUCTION
Tapentadol is a combined μ‐opioid receptor agonist 
and noradrenaline reuptake inhibitor (Frampton, 2010; 
Steigerwald, Müller, Kujawa, Balblanc, & Calvo‐Alén, 
2012; Zajączkowska et al., 2018). The involvement of both 
opioidergic and adrenergic pathways is associated with 
modulation of the endogenous pain system (Schröder, Vry, 
Tzschentke, Jahnel, & Cristoph, 2010; Zajączkowska et al., 
2018). This modulatory system is an important regulator of 
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Background: Tapentadol is a centrally acting analgesic with μ‐agonistic activity com-
bined with noradrenaline reuptake inhibition. Its mechanism of action relies on improve-
ment of descending pain inhibition. In the current study, tapentadol's ability to enhance 
conditioned pain modulation (CPM, an experimental measure of descending pain inhi-
bition) was evaluated in fibromyalgia patients with absent or reduced CPM responses.
Methods: A total of 34 fibromyalgia patients completed this double‐blind trial. 
Patients were randomized to receive treatment with tapentadol sustained‐release or 
placebo for a 3‐month period with 1‐month follow‐up. At baseline, the cornea nerve 
fibre state (CNFS) was quantified to determine the presence of nerve fibre pathology 
and assess its value in the prediction of the analgesic response.
Results: Tapentadol significantly increased CPM responses during treatment with 
an average increase from baseline of 20.5 ± 12.5% (tapentadol) versus 3.0 ± 11.2% 
(placebo; p = 0.042). No treatment effect was observed for the absolute pain scores, 
however, analgesia responder rate analyses demonstrated a treatment effect in favour 
of tapentadol. Pain relief (a reduction in pain score ≥ 30%) was predicted by the 
presence of a normal CNFS (p = 0.035). Patients with an abnormal CNFS had no 
analgesic effect from tapentadol despite an increase in CPM.
Conclusions: In chronic pain patients with fibromyalgia, the increase in endogenous 
pain inhibition by tapentadol was translated into analgesia in patients with a normal 
CNFS. In those with abnormal CNFS, tapentadol treatment was without analgesic effect.
Significance: In this double‐blind randomized placebo‐controlled trial, we showed that 
tapentadol significantly enhanced the descending pain inhibition in fibromyalgia pa-
tients. Tapentadol‐induced pain relief was only present in patients with a normal CNFS.
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normal perception of pain and engages either facilitatory or 
inhibitory pathways that interact (enhance or suppress) with 
afferent nociceptive input at the level of the spinal cord dorsal 
horn (Ossipov, Morimura, & Porreca, 2014). An imbalance 
between these opposing modulatory systems has been related 
to several chronic pain syndromes (Lewis, Rice, & McNair, 
2012). We previously showed that tapentadol treatment in 
patients with chronic pain from diabetes‐induced polyneu-
ropathy enhanced descending inhibition, as measured by 
the experimental paradigm of conditioned pain modulation 
(CPM), an effect that was correlated to tapentadol's analgesic 
efficacy (Niesters et al., 2014).
In the current study, we evaluated the ability of tapentadol 
to enhance descending inhibition in chronic pain patients 
with fibromyalgia with reduced CPM responses at baseline, 
and further assessed whether the improvement of descend-
ing inhibition was associated with reduced pain reporting. 
Fibromyalgia is a chronic pain syndrome characterized by 
widespread pain, often accompanied by a range of secondary 
symptoms including fatigue, depression and several cognitive 
and somatic disturbances (Clauw, 2014). So far, there is no 
clear pathophysiological substrate to explain the fibromyal-
gia syndrome. The most accepted hypothesis is that fibromy-
algia originates at central sites. Evidence for this comes from 
observations of increased neuronal activity during non‐nox-
ious stimulation in brain regions involved in pain perception 
and decreased activity of the descending inhibitory pain path-
way (Clauw, 2014; O'Brien, Deitos, Triñanes Pego, Fregni, & 
Carillo‐de‐la‐Peña, 2018; Schmidt‐Wilcke & Clauw, 2011).
Recent evidence suggests that the peripheral nervous sys-
tem may additionally be involved in the pathophysiology of 
fibromyalgia. Abnormalities in peripheral C‐fibres are de-
duced from the results of quantitative sensory testing and ob-
served in skin biopsies and in the upper layer of the cornea. 
The cornea contains a large number of C‐fibres that can be 
visualized with cornea confocal microscopy (CCM) (Caro & 
Winter, 2014; Doppler, Rittner, Deckart, & Sommer, 2015; 
Giannoccaro, Donadio, Incensi, Avoni, & Liguori, 2014; 
Oaklander, Herzog, Downs, & Klein, 2013; Oudejans et al., 
2016; Ramirez et al., 2015; Turan et al., 2018). The CCM 
technique allows for sensitive and reproducible evaluation of 
the presence of peripheral neuropathy and is highly correlated 
to nerve counts in skin biopsies (Jiang, Yuan, Gu, & Zhuang, 
2016; Petropoulos et al., 2013; Tavakoli et al., 2010). We and 
others recently showed that approximately 50% of fibromy-
algia patients have small fibre disease as objectified from 
 reduced density of C‐fibres in the skin or cornea (Oudejans 
et al., 2016; Ramirez et al., 2015; Turan et al., 2018).
In the current study, we hypothesize that tapentadol im-
proves descending inhibition and induces pain relief. We 
aim that tapentadol reactivates CPM responses and that 
these responses are associated with reduced pain reporting. 
Furthermore, CCM testing was performed at baseline to 
assess the prevalence of small fibre disease in our fibromyal-
gia population and to assess whether a possible improvement 
in pain reporting may be related to the cornea nerve fibre 
state (CNFS).
2 |  METHODS
2.1 | Ethics and protocol registration
This single center, double‐blind, randomized placebo‐con-
trolled trial was performed at the Anesthesia & Pain Research 
Unit of the Department of Anesthesiology of the Leiden 
University Medical Center. The study protocol was approved 
by the local Committee on Medical Ethics and the Central 
Committee on Research Involving Human Subjects in The 
Hague. From all patients included in the study, oral and writ-
ten informed consent was obtained after written information 
was provided and before enrolment in the study. The study 
was registered at the trial register of the Dutch Cochrane 
Centre under identifier 6090 and at the EU clinical Trials 
register with identification number 2015‐005258‐37 on 18 
November 2015. The study was performed between March 
2016 and March 2018. All procedures were performed in 
compliance with the current revision of the Declaration of 
Helsinki and Good Clinical Practice guidelines.
2.2 | Patients
Forty patients with fibromyalgia (diagnosed by a rheumatolo-
gist) were recruited to participate in the study. Patients were 
suitable for inclusion if they had a pain score of at least 5 of 
10 for most of the day and met the 2010 American College of 
Rheumatology diagnostic criteria (Wolfe et al., 2010). These 
criteria include a widespread pain index (WPI; 0–18 points), 
which defines the number of body areas in which a patient ex-
perienced pain during the last week and a symptom severity 
score (SyS‐score; 0–12 points), which indicates the presence 
and severity of other core symptoms of fibromyalgia such as 
fatigue, un‐refreshing sleep and cognitive symptoms. Patients 
were included if they either had a WPI ≥ 7 combined with a 
SyS‐score ≥ 5 or a WPI of 3–6 combined with a SyS‐score ≥ 9. 
Exclusion criteria included an age < 18 or > 75 years, a body 
mass index > 40 kg/m2, the presence of any medical disease 
(such as cardiovascular, pulmonary, renal, liver, cerebral or in-
fectious disease), pregnancy or lactation, a history of psychosis, 
a history of illicit drug or alcohol abuse and the use of benzodi-
azepines. Patients were asked to stop any current pain medica-
tion for at least 4 weeks before the start of the study screening.
2.3 | Study design
Patients visited the clinical research unit on five different oc-
casions. The first visit was a screening visit where a physical 
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examination was performed, baseline pain ratings were ob-
tained and CPM and CCM tests were undertaken. In case of 
a normal physical examination and an absent or diminished 
CPM response (CPM response < 12%; see statistical analysis 
section for calculation), patients were included in the study. 
After inclusion, patients were randomized to either receive 
a 12‐week daily tapentadol sustained release (Grünenthal 
GmbH, Germany) or placebo treatment. Randomization was 
performed by a third party (independent investigator) using 
a computer‐generated randomization list. This list was trans-
ferred to the local pharmacy, which was responsible for dis-
pensing of study medication. Tapentadol and placebo tablets 
were repackaged by the pharmacy for identical appearance. 
Treatment was started at a dose of 50  mg twice daily and 
weekly increased by 50–100 mg per day depending on the 
degree of pain relief and side effect profile to a maximum of 
250 mg two times a day. In case of unacceptable side effects, 
dosages were decreased to a dose were side effects were ac-
ceptable. Visits 2, 3 and 4 were planned respectively 1, 2 and 
3  months after the start of treatment. Visit 5 was planned 
1  month after treatment ended. During these visits, CPM 
tests were performed and pain scores were obtained (using 
the 100‐mm visual analogue scale, VAS). Furthermore, pa-
tients were contacted on a weekly basis by telephone to query 
for pain scores and side effects.
2.4 | Conditioned pain modulation
The CPM paradigm was performed as described previously 
(Niesters et al., 2014). In short, CPM was measured using 
heat pain as test stimulus and cold pain as conditioning 
stimulus (CS). Heat pain was applied on the volar side of 
the non‐dominant forearm with a 3  ×  3  cm thermal probe 
connected to the Pathway Neurosensory Analyzer (Medoc 
Ltd., Ramat Yishai, Israel). During heat stimulation, pa-
tients rated the pain intensity level at the skin using a slider 
on a computerized potentiometer that ranged from 0 mm (no 
pain) to 100  mm (most intense pain imaginable), allowing 
for continuous monitoring of the visual analogue scale. At 
the start of each study day, the individual test temperature 
that induced a pain score between 50 and 60  mm was de-
termined for each patient. For this, a series of heat stimuli 
were applied in which the temperature of the probe increased 
with 1.5°C/s from the baseline temperature (32°C) to a target 
temperature of various intensities (maximum 49°C) for 10 s 
after which the temperature returned to baseline (rate: 6°C/s). 
The target temperature that induced a VAS score between 50 
and 60 mm was used during the remainder of the study day. 
Also for cold pain the individual test temperature was deter-
mined. Cold pain was induced using a cold water reservoir 
(Lauda, model Alpha RA8, Lauda‐Königshofen, Germany) 
that could be set to various temperatures (range 3–25°C). The 
foot and lower leg of the patient was immersed into the water 
reservoir and the patient rated the pain intensity of the cold 
water using the VAS. The temperature that induced a VAS 
score of 30–40 mm (on a scale from 0 to 100 mm) was used 
during the remainder of the study day.
CPM was measured at three different locations on the 
volar side of the non‐dominant forearm. On each location the 
VAS score of the test stimulus (heat pain) with and without 
the conditioning stimulus (cold pain) was determined using 
the slider of the computerized potentiometer. For the test 
stimulus, the temperature of the heat probe increased with 
1.5°C/s from baseline (32°C) to the target temperature for 
10 s after which the temperature rapidly returned (6°C/s) to 
baseline. The conditioning stimulus was applied 25 s before 
the start of the test stimulus and ended simultaneously with 
the test stimulus. Patients were specifically instructed to only 
rate the pain intensity level of the test stimulus.
2.5 | Spontaneous pain ratings
To quantify spontaneous pain scores, the PainDetect ques-
tionnaire was used. This questionnaire is a screening tool to 
detect pain intensity and the presence of neuropathic pain 
symptoms. It assesses current pain intensity, pain intensity 
during the last 4 weeks, pain localization and pain qualifica-
tion (i.e. burning, tingling, sharp and stubbing). Pain intensity 
was scored using the VAS, which comprises a 100 mm line 
where the left side end indicates no pain and the right end 
side indicates the worst pain imaginable. Patients were asked 
to mark the line at a point that corresponded with their pain 
intensity level. The PainDetect questionnaire includes a neu-
ropathic symptom score that ranges from 0 to 38 points, were 
0–12 points indicates the absence of neuropathic pain, 13–18 
points indicates that a neuropathic component may be present 
and 19–38 points indicates that a neuropathic component is 
likely present.
2.6 | Cornea confocal microscopy
CCM was performed on both eyes using the Rostock Cornea 
Module of the Heidelberg Retina Tomograph III (Heidelberg, 
Germany). After topical anaesthesia of both eyes the mi-
croscope was placed at the surface of the cornea apex and 
images were acquired with a 400  ×  400  µm field of view 
and quantified using ACCmetrics software (provided by the 
faculty of Medical and Human Sciences of the University of 
Manchester, United Kingdom). Next, 3–10 representative, 
high‐quality images per eye were manually selected by a 
blinded investigator, which were used for quantification of 
the cornea nerve fibre length (CNFL), cornea nerve fibre den-
sity (CNFD) and cornea nerve branching density (CNBD). 
Each of these parameters for small nerve fibre pathology of 
the cornea were then compared to a reference value set pub-
lished by Tavakoli et al. (2015). Small nerve fibre pathology 
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was considered present if 2 of 3 parameters were defined as 
abnormal.
2.7 | Sample size and statistical analyses
We did not perform a formal sample size analysis as no data 
were available on the efficacy of tapentadol on CPM in fi-
bromyalgia patients. Based on the results of a previous study 
(Niesters et al., 2014), where patients were not selected on 
the absence of CPM prior to enrolment, the inclusion of 15 
patients per group would result in a power > 90% to detect 
a 25% increase in CPM with a standard deviation of 20% for 
tapentadol treatment compared to placebo (alpha  =  0.05, 
two‐tailed). We included an extra five patients per group to 
consider any margin of uncertainty around the effect size and 
SD and to compensate for expected drop outs due to the long 
study period.
All variables were screened for missing data, distribu-
tion abnormalities and outliers. Baseline characteristics were 
analysed with the appropriate parametric or non‐parametric 
tests. CPM responses were calculated using the area under 
the curve values of the electronic collected VAS data during 
the test stimulus with and without the conditioning stimu-
lus. Averages of the three AUC responses per condition were 
calculated. To correct for variation in the magnitude of the 
responses between sessions and between subjects the rela-
tive CPM was calculated as: CPM% = [(mean AUC without 
CS − mean AUC with CS)/(mean AUC without CS)] × 100. 
The overall treatment effect (corrected for baseline) on the 
CPM% responses and the spontaneous pain scores (visits 
1–4) were analysed using a mixed model with treatment as 
fixed effect and patient as random effect to account for re-
peated measurements over time. Similar analyses were per-
formed on the CPM% responses and pain scores as function 
of CCM. The absolute pain scores were correlated to the 
CPM% responses and the neuropathic symptom score of the 
PainDetect questionnaire by Spearmans ρ. An analgesia re-
sponder rate analysis was performed to evaluate the propor-
tion of patients who achieved predefined response rates in 
the range between 0% and 100%. The response rate was cal-
culated by the proportion of pain relief compared to baseline 
measured at two time points during the treatment period (vis-
its 2–4) compared to baseline. A Kolmogorov–Smirnov test 
was used to compare treatment distributions. CCM responses 
(normal vs. abnormal) between the different treatment re-
sponder groups and the correlation between CCM and the 
neuropathic symptom score of the PainDetect questionnaire 
were compared with a Fisher's exact test. A binary logistic 
regression was used to determine whether the CNFS was able 
to predict treatment responses where a treatment responder 
was defined by a reduction in pain reporting of at least 30%. 
SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for 
Windows, Version 25.0. Armonk, NY: IBM Corp.) was used 
for all analyses, p‐values < 0.05 (two‐tailed) were considered 
significant. All data are reported as mean ± SD unless oth-
erwise stated.
3 |  RESULTS
A total of 67 patients were assessed for eligibility of whom 
27 were excluded because they did not meet the inclusion 
criteria; 40 patients were randomized to treatment. Six pa-
tients (five in the tapentadol group, one in the placebo group) 
did not complete the study period mostly due to unacceptable 
side effects. Since this occurred in the first weeks of treat-
ment (before the measurement at month 1), analysis was per-
formed only on the patients who completed the whole study 
period. See Figure 1 for the flowchart of the study. No sig-
nificant differences were observed in baseline characteristics 
between the two study group. According to the PainDetect 
questionnaire, a neuropathic pain component was likely pre-
sent in 60% of patients and possibly present in another 30% 
(Table 1). The average drug dose after the titration period was 
340 ± 91 mg/day in the tapentadol group and 384 ± 129 mg/
day in the placebo group. Side effects were reported in 14 of 
15 patients in the tapentadol group and 14 of 19 patients in 
the placebo group. Reported side effects are listed in Table 
2. Nausea was observed more frequently in patients treated 
with tapentadol (p = 0.005). Furthermore, although not sig-
nificant, more patients in the tapentadol group reported opi-
oid related side effects.
3.1 | Conditioned pain modulation
Average heat pain temperatures used to induce the CPM 
paradigm were 43.8  ±  3.1°C for the tapentadol group and 
43.5 ± 2.4°C for the placebo group (p = 0.708), which in-
duced pain scores of respectively 61.3  ±  17.4  mm and 
57.9 ± 15.4 mm (p = 0.655). Average cold pain temperatures 
were for the tapentadol group 11.5 ± 6.3°C and 11.2 ± 6.7°C 
for the placebo group (p  =  0.896). Corresponding pain 
scores were 40.0 ± 1.7 mm and 42.0 ± 1.9 mm respectively 
(p = 0.723). Before treatment no difference was observed in 
the magnitude of the CPM responses between the two treat-
ment groups with a CPM% score of −4.0 ± 17.4% for the 
tapentadol group and 1.8  ±  13.9% for the placebo group 
(p  =  0.297). CPM% responses increased during treatment 
with tapentadol with an average increase compared to base-
line of 20.5 ± 12.5% for tapentadol compared to 3.0 ± 11.2% 
for placebo (mixed model visit 1–4: p = 0.042; see Figure 2).
3.2 | Spontaneous pain scores
Average spontaneous pain scores did not differ between 
the two groups before the start of treatment with a reported 
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VAS score of 62.0 ± 13.1 mm for the tapentadol group and 
62.1 ± 14.0 mm for the placebo group (p = 0.929). Overall, 
no significant difference in pain scores were observed during 
the 3‐month treatment period between tapentadol and placebo 
(mixed model visit 1–4: p  =  0.115, Figure 3a). Analgesia 
responder rates for both treatments are plotted in Figure 3b 
for deciles ranging from 0% pain relief to 100% pain relief. 
This analysis demonstrated a treatment effect in favour of 
tapentadol (p = 0.007). No correlation was observed between 
pain scores and the neuropathic symptom score.
3.3 | Analgesia versus CPM
Patients with at least a 30% reduction of pain reporting were 
defined as either treatment or placebo responder. A highly 
significant correlation was observed between absolute pain 
scores and corresponding CPM% values per visit when all 
treatment responders (tapentadol and placebo) were taken 
together (r2 = 0.60, p = 0.008). The correlation still existed 
when the treatment responder groups were analysed sepa-
rately, but at a borderline significant level probably due to the 
smaller sample size (tapentadol responder group: r2 = 0.78, 
p = 0.047; placebo responder group r2 = 0.76, p = 0.055; 
Figure 4a,b). No correlation between absolute pain scores 
and CPM% values was observed in the non‐responder groups 
(Figure 4c,d). Overall, these data indicate that although tap-
entadol was able to increase CPM responses in a majority of 
patients this enhancement of CPM led to analgesia in only a 
subgroup of patients.
3.4 | Cornea confocal microscopy
Before the start of treatment each patient was photo-
graphed using CCM to evaluate the quantity and quality 
of the small nerve fibres in the cornea. Abnormal CCM 
images were observed in 38% of patients (see also Table 
3). Interestingly, normal CCM images were observed in 
87.5% of patients in the tapentadol responder group (eight 
of nine patients) compared to 12.5% of the patients in the 
tapentadol non‐responder group (one of six; p  =  0.041). 
F I G U R E  1  Flowchart of the study. BMI, body mass index; CPM, conditioned pain modulation






Men/women (n) 1/14 1/18
Age (years)—median 
(range)
46.2 (23–62) 42.4 (24–67)
Weight (kg)—mean (SD) 78.7 (17.3) 81.8 (16.4)
Height (cm)—mean (SD) 1.70 (0.1) 1.72 (0.1)
Widespread Pain Index—
mean (SD)
13.1 (3.0) 13.5 (3.1)
Symptom Severity 
Score—mean (SD)
9.2 (1.5) 8.8 (1.4)
Disease duration (years) 5.4 (4.9) 4.8 (3.8)
PainDetect
Pain intensity score 
(mm)—mean (SD)
62.0 (13.1) 62.1 (14.0)
Neuropathic symptom 
score—mean (SD)
19.7 (6.5) 19.8 (5.8)
Score 13–18 (n, %) 5 (33.3) 5 (26.3)
Score 19–38 (n, %) 9 (60.0) 12 (63.2)
Abbreviation: SD, standard deviation.
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In the placebo group CCM images were similarly af-
fected in both responder groups: 33.3% of the treatment 
responders (two of six) and 28.5% of the treatment non‐
responders (4 of 13) had normal CCM images (Figure 5). 
Moreover, CCM was able to predict the treatment response 
in patients in the tapentadol group (p = 0.035) with a nor-
mal CNFS as predictor for tapentadol induced analgesia. 
CCM was not able to predict treatment effects in patients 
treated with placebo (p = 0.465). In Figure 6 the changes 
in CPM% and pain scores are presented as a function of 
CCM (normal vs. abnormal) for the patients treated with 
tapentadol. While the CPM response was not associated 
with the CCM status (Figure 6a), patients with normal 
CCM images displayed more pain relief, albeit not signifi-
cant (Figure 6b; p = 0.104). No correlation was observed 
between CCM status and the neuropathic symptom score at 
baseline (p = 0.580).
4 |  DISCUSSION
In the current study, we evaluated the effect of a 3‐month 
tapentadol treatment on the endogenous pain modulatory 
system in fibromyalgia patients. In summary, we observed 







Nausea 11 (73) 4 (21) 0.005
Dizziness 4 (27) 4 (21) 1.000
Headache 3 (20) 10 (53) 0.079
Dry mouth 1 (7) 0 (0) 0.441
Somnolence 4 (27) 1 (5) 0.146
Itch 4 (27) 1 (5) 0.146
Constipation 5 (33) 2 (11) 0.199
Shortness of 
breath
2 (13) 0 (0) 0.187
Palpitations 1 (7) 0 (0) 0.441
Weariness 3 (20) 2 (11) 0.634
Sweating 2 (13) 0 (0) 0.187
Depressive 
symptoms
2 (13) 0 (0) 0.187
Euphoria 1 (7) 0 (0) 0.441
Blurred vision 1 (7) 0 (0) 0.441
Muscle 
cramps
1 (7) 0 (0) 0.441
F I G U R E  2  Change in CPM response relative to baseline before, 
during and after treatment with tapentadol (green circles) or placebo 
(orange squares). A significant treatment effect on CPM was observed 
for tapentadol compared to placebo (p = 0.042). The grey bar indicates 
the treatment period. Data are mean ± SEM. CPM, conditioned pain 
modulation
F I G U R E  3  (a) Change in pain score compared to baseline 
before, during and after treatment with tapentadol (green circles) or 
placebo (orange squares). The grey bar indicates the treatment period. 
(b) Graph of the analgesia responder rate for predefined response rates 
in the range between 0% to 100%
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that tapentadol in contrast to placebo significantly in-
creased the efficacy of the descending inhibitory pain path-
way as measured by CPM. Patients with a normal cornea 
fibre state had an increase in CPM and displayed pain relief 
during tapentadol treatment. In contrast, patients with an 
abnormal cornea nerve state had no pain relief from tapen-
tadol despite an increase in CPM.
The only earlier evidence in humans that tapentadol is 
able to increase descending pain inhibition comes from one 
previous study (Niesters et al., 2014). In this study, a 1‐month 
treatment period with tapentadol significantly increased 
CPM responses in patients with diabetic polyneuropathy. In 
agreement with that study, tapentadol also enhanced descend-
ing inhibition in the current study, which suggests a general 
beneficiary role of tapentadol in increasing CPM in multi-
ple chronic pain conditions with absent or reduced CPM. 
Tapentadol is thought to increase CPM by its synergistic 
mode of action, which includes activation of the µ‐opioid re-
ceptor and noradrenaline reuptake inhibition (Zajączkowska 
et al., 2018). Both neurotransmitter systems are important in 
the activation of descending inhibition at supraspinal sites as 
well as at the level of the spinal cord dorsal horn (Ossipov 
et al., 2014). For example, microinjection of opioids in the 
periaqueductal grey, an important regulator of descending 
inhibition, produces powerful antinociception in animals. 
Furthermore, numerous animal studies showed that chemical 
and electrical stimulation of noradrenergic nuclei in the brain 
enhanced pain inhibition by release of norepinephrine into 
the cerebrospinal fluid. Spinally administered α2‐adrenergic 
agonists have been shown to induce antinociception in both 
animals and humans with a strong antinociceptive synergy 
when combined with opioids. See for an excellent review on 
this topic the study by Ossipov et al. (2014).
We studied fibromyalgia patients with absent or reduced 
CPM responses. About one‐third of fibromyalgia patients 
in our initial sample had relatively normal CPM responses 
(Figure 1). This, together with our observation of cornea 
nerve fibre abnormalities in a subset of patients, are indica-
tions of the large heterogeneity in the fibromyalgia patient 
population with respect to underlying pathophysiological 
mechanisms that determine development and/or maintenance 
of fibromyalgia symptoms, and additionally may explain the 
variations in success rate of pharmacological therapy. We a 
priori argued that patients with an absent or reduced CPM 
response were the most likely to benefit from treatment with 
tapentadol. Hence, a patient with a normal CPM response 
prior to treatment will likely still have a normal CPM re-
sponse after treatment (i.e. a CPM response > 12%). Given 
our results, an important issue is whether the increase in CPM 
is the primary cause of the analgesic response or whether sec-
ondary conditions play an equally important role. The obser-
vation that not all subjects showed an analgesic effect from 
F I G U R E  4  CPM% versus 
spontaneous pain ratings for the different 
visits in the (a) tapentadol responder group 
(closed green circles), the (b) placebo 
responder group (closed orange squares), the 
(c) tapentadol non‐responder group (open 
green circles) and the (d) placebo non‐
responder group (open orange squares). A 
significant correlation was only observed for 
the tapentadol responder group (r2 = 0.78; 
p = 0.047; green dotted line). Data are 
mean ± SEM. CPM, conditioned pain 
modulation; VAS, visual analogue scale; 
V1, visit 1; V2, visit 2; V3, visit 3; V4, visit 
4; V5, visit 5










13 (38) 7 (47) 6 (32)
CNFD (n/mm2) 15.3 14.7 15.8
CNBD (n/mm2) 20.7 18.8 22.3
CNFL (n/mm2) 13.6 13.4 13.8
Abbreviations: CCM, cornea confocal microscopy; CNBD, cornea nerve 
branching density; CNFD, cornea nerve fibre density; CNFL, cornea nerve fibre 
length; PLC, placebo; TPT, tapentadol.
aRelative to reference value (Tavakoli et al., 2015). 
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tapentadol despite a significant increase in CPM (Figure 5) 
points towards the later suggestion. For example, one factor 
for the successful translation of reactivated CPM into pain 
relief may be the CNFS (see below). Evidently, other yet un-
specified factors may be involved as well.
The large heterogeneity within the fibromyalgia pop-
ulation, but also within other chronic pain syndromes, 
mandates a mechanism‐based approach when introduc-
ing pharmacological (and possibly also non‐pharmaco-
logical) treatment. As discussed earlier, it is important to 
stratify patients in homogeneous subgroups according to 
patterns of disease symptoms, (psycho)physical tests and 
underlying pathology (Cruz‐Almeida & Fillingim, 2014; 
Forstenpointer, Rehm, Gierthmühlen, & Baron, 2018; 
Oudejans et al., 2016; Oudejans, Niesters, Dahan, Brines, 
& Velzen, 2017). Specific symptoms or signs may then be 
used to predict treatment efficacy. Currently, there is some 
evidence for such predictive factors. For example, in post‐
herpetic neuralgia patients, mechanical allodynia was as-
sociated with lidocaine efficacy (Attal, Rouaud, Brasseur, 
Chauvin, & Bouhassira, 2004), while heat pain thresholds 
correlated with opioid effect. Patients with chronic pancre-
atitis and a higher sensitivity to electrical stimulation in the 
pancreatic area were more likely to experience analgesia 
from pregabalin (Olesen et al., 2013). Also CPM is a known 
predictor of treatment efficacy. A less efficient CPM was 
correlated to duloxetine efficacy in patients with painful 
diabetic neuropathy (Yarnitsky, Granot, Nahman‐Averbuch, 
Khamaisi, & Granovsky, 2012), while patients with knee 
osteoarthritis and a more efficient CPM were more likely 
to show pain reduction during treatment with diclofenac 
(Edwards et al., 2016).
In the current study, we used CCM to phenotype patients 
according to their CNFS and showed that the nerve fibre 
condition was able to predict the tapentadol treatment ef-
fect. CCM is a relatively new technique to quantify small 
nerve fibres in the cornea. The technique has been validated 
in several patient populations with peripheral neuropathy in 
which good correlations were observed between the nerve 
fibre density in the cornea and in skin biopsies (Jiang et al., 
2016; Petropoulos et al., 2013; Tavakoli et al., 2010). In 
the current study, tapentadol's analgesic efficacy was high-
est in patients with a normal CNFS. In fact, the responder 
rate was over 85% in this subset of patients (Figure 5). The 
reason for observed causality remains unknown. The ab-
normal CCM findings may be an indication of a more ad-
vanced disease state with a lesser sensitivity to treatment. 
Alternatively, we may have been studying two distinct pa-
tient phenotypes with a different sensitivity to treatment. 
An important observation is that, in line with previous 
findings, there was no correlation between CCM abnor-
malities and neuropathic symptom score of the PainDetect 
questionnaire (Oudejans et al., 2016). We do not know 
why these two indicators of neuropathy do not align in our 
F I G U R E  5  Percentage of patients 
with normal and abnormal cornea confocal 
microscopy images for the different 
responder groups in patients treated with 
(a) tapentadol or (b) placebo. CCM, cornea 
confocal microscopy; PLC, placebo; TPT, 
tapentadol
F I G U R E  6  Change in CPM% (a) and pain scores (b) before, during and after treatment as function of cornea confocal microscopy images for 
the patients treated with tapentadol. The CPM response was not associated with the CCM status. Patients with normal CCM images displayed more 
pain relief, albeit not significant (p = 0.104). CCM, cornea confocal microscopy; CPM, conditioned pain modulation; VAS, visual analogue scale
   | 9van de dOnK et al.
fibromyalgia patient sample. Possibly, the development of 
pain symptoms and small fibre abnormalities are incongru-
ent over the life cycle.
A limitation of the current study is the relatively small 
sample size. Still, we believe that due to the strict patient 
inclusion criteria our primary outcome measurements (en-
hancement of CPM) may be interpreted with reasonable re-
liability. The study was not powered to detect a difference 
in pain reporting and significant analgesic responses are not 
expected with these low numbers. Our secondary outcome 
measurement, the ability of the CNFS to predict treatment 
efficacy should be seen as hypothesis generating and needs 
further research in a large patient population to confirm or 
disclaim our findings. Another limitation of our study is that 
our conclusions are restricted to fibromyalgia patients with 
an impaired CPM response. It is of interest to assess tapen-
tadol's analgesic efficacy in patients with fibromyalgia and 
normal CPM responses, and determine the role of the cornea 
nerve state on response efficacy.
Finally, it is important to discuss the use of tapentadol 
in this patient population in light of the current opioid epi-
demic. Tapentadol is a bifunctional analgesic at two distinct 
(one opioid and one non‐opioid) receptors to induce syner-
gistic analgesic responses (Zajączkowska et al., 2018). It has 
a better safety index than classical opioid agonists such as 
oxycodone (Van der Schrier et al., 2017). We therefore do 
see some indication for its use in a subset of chronic pain 
patients, especially when treatment is restricted to periods 
no longer than 3  months, to allow an initial effective sup-
pression of pain symptoms and most importantly to allow 
time to determine next treatment steps. However, our study 
suggests that the patients’ eligibility to such treatment may 
require phenotyping. Further studies are required to expand 
the process of phenotyping and assess whether phenotyping 
will lead to a reduction in the opioid adverse effects including 
(and most importantly) addiction and respiratory depression.
In conclusion, in the current study we demonstrate that 
a 3‐month treatment period with tapentadol significantly in-
creased descending pain inhibition in fibromyalgia patients 
with reduced descending pain inhibition prior to treatment. 
Furthermore, tapentadol‐induced significant analgesia which 
was correlated to the magnitude of CPM increase, but only in 
patients with a normal CNFS.
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